## Clinical Context This patient has confirmed influenza B with severe presentation: hypoxemia (SpO₂ 88%), tachypnea (RR 28), bilateral infiltrates on imaging, and significant comorbidities (COPD, diabetes). This constitutes severe influenza with risk of complications. ## Severity Assessment | Feature | This Patient | Implication | |---------|--------------|-------------| | Age | 72 years | High-risk group | | Comorbidities | COPD, diabetes | Increased mortality risk | | Hypoxemia | SpO₂ 88% | Severe | | Infiltrates | Bilateral | Pneumonia (viral ± secondary bacterial) | | Respiratory rate | 28/min | Respiratory distress | **Key Point:** Severe influenza requires hospitalization, antiviral therapy, supplemental oxygen, and microbiological workup to exclude secondary bacterial infection. ## Management Steps 1. **Admission** — Severe hypoxemia and bilateral infiltrates mandate inpatient care 2. **Antivirals** — Oseltamivir 75 mg orally BD × 5 days (or IV peramivir if unable to take orally) 3. **Oxygenation** — Supplemental O₂ to target SpO₂ ≥ 94% 4. **Microbiological workup** — Blood cultures and sputum culture to identify secondary bacterial pathogens (S. pneumoniae, H. influenzae, S. aureus) 5. **Supportive care** — Fluids, monitoring, consider ICU if worsening **High-Yield:** Bilateral infiltrates in influenza suggest either severe viral pneumonia or secondary bacterial superinfection — cultures are essential to guide antibiotic therapy if needed. **Clinical Pearl:** Oseltamivir is still beneficial in hospitalized patients even beyond 48 hours, especially in severe disease. It reduces ICU admission and mortality. ## Why Not Zanamivir? Zanamivir is inhaled and contraindicated in patients with underlying airway disease (COPD) due to risk of bronchospasm. Oseltamivir (oral) is preferred.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.